For Patients

What is the SENATOR project about?

SENATOR is an ambitious €6M project funded by the European Union under FP7 Programme under the topic “Active and Healthy Ageing”.

The SENATOR project started in 2012 and is focused on the development of a highly-powered and efficient software engine (SENATOR) capable of individually screening the clinical status and pharmacological and non- pharmacological therapy of older people with multi-morbidity in order to define optimal drug therapy, highlight ADR risk and provide advice on appropriate non-pharmacological therapy.

The first phase of SENATOR was the development of the SOFTWARE by ClanWilliam Health LTD. The functional software was tested and validated by comparison with a gold standard i.e. two experienced expert clinicians assessing the medication lists of 20 cases of older people with multiple chronic medical conditions and associated polypharmacy (multiple medications). Following the successful testing and validation of SENATOR software, the SENATOR consortium then embarked on a clinical trial to test the SENATOR software as an intervention compared with usual medication assessment. With the data from this  randomised controlled multicenter clinical trial involving  older people with multi-morbidity who are hospitalized with acute illnesses that are treated in hospital by specialists (other than geriatricians and clinical pharmacologists), the SENATOR consortium hopes to determine whether or not SENATOR software-assisted medication review offers a significant advantage over current routine medication review by attending clinicians and pharmacists in terms of reduced adverse drug reactions and associated healthcare costs as well as patient quality of life.

What patients are enrolled in SENATOR?

The SENATOR clinical trial is enrolling older people admitted to hospital with acute illnesses of many kinds under the care of clinicians other than specialists in Geriatric Medicine and Clinical Pharmacology (in order to avoid introducing bias into the trial).

Which are the clinical sites?

Cork University Hospital

Principal Investigator: Prof. Dr. Denis O´Mahony

Ghent University Hospital

Principal Investigator: Prof. Mirko Petrovic
DECT: 22366
Primary Researcher: Lore Vandaele
DECT: 22356

Hospital Universitario Ramón y Cajal, Servicio de Geriatría

Principal Investigator: Dr. Alfonso Cruz Jentoft
Dra. Isabel Lozano Montoya
Andrea Correa Pérez
tel: 29127, 88172  geriatria.hrc(at)salud.madrid.org 

Geriatria INRCA

Principal Investigator: Prof. Antonio Cherubini
Tel: 0718003284

Landspitali Reykjavik

Principal Investigator: Prof. Aðalsteinn Guðmundsson
Study coordinator: Ástrós Sverrisdóttir
SENATOR tel: 543 1159 / 825 9450

Aberdeen Royal Infirmary

Principal Investigator: Dr Roy Soiza
Phone: +44 (0) 1224 558109; Bleep 4244
Primary Researcher: Selva Subbarayan
Phone: +44 (0) 1224 552413

How can patients benefit from the results in SENATOR clinical trial and SENATOR software?

Older people with multi-morbid illness (multiple simultaneous chronic medical conditions) and associated polypharmacy (numerous daily medications) are at substantial risk of adverse drug reactions (ADRs), particularly when they are hospitalized with acute illness. The SENATOR software is designed to reduce adverse drug reactions by means of identifying and avoiding potentially inappropriate medications (PIMs), potential prescribing omissions (PPOs), potentially adverse drug-drug interactions and drug-disease interactions. If the SENATOR trial shows significantly fewer ADRs, better quality of life and less need for healthcare in general in the intervention cohort of patients compared to the control cohort receiving standard medication care, there will be a very strong case for the routine application of software-based medication review of this kind in routine clinical practice globally.